{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:44:44Z","timestamp":1783115084090,"version":"3.54.6"},"reference-count":75,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Canagliflozin is a synthetic sodium glucose transporter inhibitor (SGLT2i). It is\n                    the latest approved class of medicine used in the treatment of type 2 diabetes\n                    mellitus. As diabetes is emerging as the most common metabolic disorder, SGLT2i\n                    has lightened up the path of treatment with additional benefits. SGLT2 is\n                    located in the proximal convoluted tubules of the nephron and is responsible for\n                    glucose reabsorption. Thus, inhibiting the SGLT2 leads to a decline in glucose\n                    concentration in the plasma. The secondary effects of canagliflozin, such as\n                    cardiac protection, renoprotective, and decreased obesity, have made it more\n                    putative in the treatment of diabetes mellitus. There are some side effects of\n                    canagliflozin, such as volume depletion, genital and urinary tract infection,\n                    and lower limb amputation, which could be a matter of concern for patients.\n                    Being an anti-diabetic drug, canagliflozin also possesses anti-inflammatory and\n                    anti-cancer properties. Several studies have been conducted to determine the\n                    efficacy of canagliflozin as an anti-cancer agent. Its pharmacokinetics indicate\n                    rapid absorption, reaching peak plasma concentrations within 1\u20132\u2009hours. With a\n                    half-life of approximately 12\u2009hours, it undergoes minimal hepatic metabolism and\n                    is primarily excreted unchanged via urine. Common adverse drug reactions (ADRs)\n                    include urinary tract infections and dehydration. Clinical trials on\n                    canagliflozin, both alone and in combination with other diabetes complications,\n                    have been conducted, with some completed and others in various phases. This\n                    review article contains information about the pharmacokinetics, drug safety, and\n                    efficacy profile of canagliflozin, along with details regarding toxicological\n                    studies of canagliflozin.<\/jats:p>","DOI":"10.1055\/a-2577-1899","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:40:46Z","timestamp":1745880046000},"page":"183-201","source":"Crossref","is-referenced-by-count":3,"title":["Canagliflozin: A Comprehensive Review of Advances in Preclinical\n                    Research"],"prefix":"10.1055","volume":"75","author":[{"given":"Bushra","family":"Imran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integral University, Dasauli, Kursi Road,\n                    Lucknow (U.P), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farogh","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integral University, Dasauli, Kursi Road,\n                    Lucknow (U.P), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarique","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integral University, Dasauli, Kursi Road,\n                    Lucknow (U.P), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Masih Uzzaman","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, College of\n                    Pharmacy, Qassim University, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzadi","family":"Bano","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Integral University, Kursi Road, Dasauli,\n                    Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mehdi Hasan","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integral University, Dasauli, Kursi Road,\n                    Lucknow (U.P), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal Akhtar","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Integral University, Kursi Road, Dasauli,\n                    Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Integral University, Dasauli, Kursi Road,\n                    Lucknow (U.P), India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/J.DIABRES.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for\n                    2030 and 2045: Results from the International Diabetes Federation Diabetes\n                    Atlas","volume":"157","author":"P Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.4103\/IJO.IJO_1627_21","article-title":"Epidemiology of type 2 diabetes in India","volume":"69","author":"R Pradeepa","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e2004","DOI":"10.1002\/HSR2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: Early\n                    detection should be focused","volume":"7","author":"M J Hossain","year":"2024","journal-title":"Heal Sci Reports"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"115734","DOI":"10.1016\/J.BIOPHA.2023.115734","article-title":"Diabetes mellitus: Classification, mediators, and complications; A gate to\n                    identify potential targets for the development of new effective treatments","volume":"168","author":"S A Antar","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2337\/DC25-SREV","article-title":"Summary of Revisions: Standards of Care in Diabetes\u20142025","volume":"48","author":"ADAP P Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jdi.14150","article-title":"Changing landscape of diabetes in Asia\u2013What are the unmet needs?","volume":"15","author":"A Luk","year":"2024","journal-title":"J Diabetes Investig"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12982-025-00426-8","article-title":"Prevalence of diabetes and prediabetes in South Asian countries: a systematic\n                    review and meta-analysis","volume":"22","author":"M Ali","year":"2025","journal-title":"Discov Public Heal"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/J.DSX.2024.103160","article-title":"Rising trends of diabetes in South Asia: A systematic review and\n                    meta-analysis","volume":"18","author":"P Ranasinghe","year":"2024","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"151329","DOI":"10.1016\/J.EJCB.2023.151329","article-title":"Recent trends and advances in type 1 diabetes therapeutics: A comprehensive\n                    review","volume":"102","author":"A Singh","year":"2023","journal-title":"Eur J Cell Biol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1440456","DOI":"10.3389\/FENDO.2024.1440456\/BIBTEX","article-title":"A critical review on diabetes mellitus type 1 and type 2 management approaches:\n                    from lifestyle modification to current and novel targets and therapeutic\n                    agents","volume":"15","author":"B A Tegegne","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"116185","DOI":"10.1016\/J.EJMECH.2024.116185","article-title":"A comprehensive review of small-molecule drugs for the treatment of type 2\n                    diabetes mellitus: Synthetic approaches and clinical applications","volume":"267","author":"Y Y Guo","year":"2024","journal-title":"Eur J Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DMSO.S184437","article-title":"Canagliflozin review \u2013 safety and efficacy profile in patients with T2DM","volume":"12","author":"H Jakher","year":"2019","journal-title":"Diabetes, Metab Syndr Obes Targets Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1573399811666150618143948","article-title":"A Systematic Review on Effect of Canagliflozin in Special Population","volume":"12","author":"S Patel","year":"2016","journal-title":"Curr Diabetes Rev"},{"key":"ref14","first-page":"1303","article-title":"An Overview of Canagliflozin","volume":"13","author":"A Ganguly","year":"2024","journal-title":"World J Pharm Pharm Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/1947-2714.128471","article-title":"Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus","volume":"6","author":"S Kaushal","year":"2014","journal-title":"N Am J Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4137\/CMED.S31526","article-title":"Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus","volume":"8","author":"C Triplitt","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/2230-8210.196016","article-title":"A review of clinical efficacy and safety of canagliflozin 300 mg in the\n                    management of patients with type 2 diabetes mellitus","volume":"21","author":"K Prasanna","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1021\/JM100332N","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as\n                    sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2\n                    diabetes mellitus","volume":"53","author":"S Nomura","year":"2010","journal-title":"J Med Chem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1177\/1060028013503626","article-title":"Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes","volume":"47","author":"S C Nigro","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/S12325-015-0234-0","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese\n                    Patients with Type 2 Diabetes Mellitus","volume":"32","author":"H Iijima","year":"2015","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/S40262-015-0285-Z","article-title":"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of\n                    Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor","volume":"54","author":"D Devineni","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/JCPH.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose\n                    co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"D Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2\n                    diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results\n                    from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"W T Cefalu","year":"2013","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/17512433.2014.864950","article-title":"Canagliflozin versus glimepiride treatment in patients with type 2 diabetes\n                    inadequately controlled with metformin (CANTATA-SU trial)","volume":"7","author":"S N Davis","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/DOM.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2\n                    diabetes on background metformin and pioglitazone","volume":"16","author":"T Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/IJCP.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus\n                    inadequately controlled with metformin and sulphonylurea: a randomised\n                    trial","volume":"67","author":"JP H Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2337\/DC11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2\n                    inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"J Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/J.AMJCARD.2017.05.012","article-title":"EMPA-REG OUTCOME: The Nephrologist\u02bcs Point of View","volume":"120","author":"C Wanner","year":"2017","journal-title":"Am J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/S13300-019-00686-Z","article-title":"The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the\n                    Glycemic Benefit","volume":"10","author":"D K Patel","year":"2019","journal-title":"Diabetes Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus:\n                    Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical\n                    Applications","volume":"134","author":"H Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/J.AJKD.2018.03.022","article-title":"SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A\n                    Review","volume":"72","author":"R Z Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1172\/JCI167700","article-title":"Digging deep into cells to find mechanisms of kidney protection by SGLT2\n                    inhibitors","volume":"133","author":"K R Tuttle","year":"2023","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links\n                    the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart\n                    Failure","volume":"136","author":"M Packer","year":"2017","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"F2","DOI":"10.1152\/AJPRENAL.00614.2014","article-title":"Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon,\n                    vasopressin, and urea","volume":"309","author":"L Bankir","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1086672","DOI":"10.3389\/FCVM.2022.1086672","article-title":"Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood\n                    pressure","volume":"9","author":"T W Kao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.BCP.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular\n                    glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"C Xu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/S10557-020-07083-W","article-title":"Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in\n                    Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells","volume":"35","author":"L Uthman","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1038\/S41598-020-71449-1","article-title":"Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by\n                    stimulating multiple antioxidant and anti-inflammatory signaling pathways","volume":"10","author":"R Hasan","year":"2020","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8777","DOI":"10.3390\/IJMS23158777","article-title":"Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction\n                    of Heme Oxygenase-1","volume":"23","author":"K J Peyton","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"114228","DOI":"10.1016\/J.BIOPHA.2023.114228","article-title":"Canagliflozin inhibits inflammasome activation in diabetic endothelial cells \u2013\n                    Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on\n                    human diabetic endothelial cells","volume":"159","author":"X Li","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.52711\/0974-360X.2022.00747","article-title":"Evaluation of Anti-Inflammatory and Wound Healing Potential of Sodium Glucose\n                    Co-Transporter2 (SGLT2) Inhibitors","volume":"15","author":"R Nandhidha","year":"2022","journal-title":"Res J Pharm Technol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/DOM.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"C J Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.3390\/IJERPH20176671","article-title":"Immunomodulatory Effects of SGLT2 Inhibitors-Targeting Inflammation and\n                    Oxidative Stress in Aging","volume":"20","author":"E Sch\u00f6nberger","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/EURJHF\/HFT132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"H Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/J.AMJMED.2006.06.040","article-title":"Prevalence of the metabolic syndrome in individuals with hyperuricemia","volume":"120","author":"H K Choi","year":"2007","journal-title":"Am J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2337\/DC11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type\n                    2 diabetes and preserved kidney function","volume":"35","author":"G Zoppini","year":"2012","journal-title":"Diabetes Care"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/J.JCJD.2014.10.013","article-title":"Uric acid as a biomarker and a therapeutic target in diabetes","volume":"39","author":"Y Lytvyn","year":"2015","journal-title":"Can J Diabetes"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"110669","DOI":"10.1016\/J.DIABRES.2023.110669","article-title":"Perspectives in weight control in diabetes \u2013 SGLT2 inhibitors and GLP-1\u2013glucagon\n                    dual agonism","volume":"199","author":"N Iqbal","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.3390\/CANCERS14235811","article-title":"SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New\n                    Perspectives","volume":"14","author":"M Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/S00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and\n                    meta-analysis of randomised controlled trials","volume":"60","author":"H Tang","year":"2017","journal-title":"Diabetologia"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/J.MOLMET.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by\n                    inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"L A Villani","year":"2016","journal-title":"Mol Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/S41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking\n                    glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"M H Hung","year":"2019","journal-title":"Cell Death Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"G R Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"473","DOI":"10.18203\/2319-2003.IJBCP20190459","article-title":"Evaluation and comparison of anti-cancer activity of dapagliflozin and\n                    canagliflozin in oral cancer cell line: an in vitro study","volume":"8","author":"N Vinay","year":"2019","journal-title":"Int J Basic Clin Pharmacol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1057455","DOI":"10.3389\/FONC.2022.1057455\/FULL","article-title":"Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer\n                    metastasis","volume":"12","author":"D Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/S13340-021-00494-6","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer\n                    cell proliferation in vitro","volume":"12","author":"L Yamamoto","year":"2021","journal-title":"Diabetol Int"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/S10571-022-01221-8","article-title":"Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating\n                    AMPK","volume":"43","author":"K Shoda","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/S42003-023-05289-W","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer\n                    response to radiotherapy","volume":"6","author":"A Ali","year":"2023","journal-title":"Commun Biol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMOA1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"117414","DOI":"10.1016\/J.LFS.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty\n                    acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"D Wei","year":"2020","journal-title":"Life Sci"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/DOM.14508","article-title":"Effects of 1-year treatment with canagliflozin on body composition and total\n                    body water in patients with type 2 diabetes","volume":"23","author":"I Matsuba","year":"2021","journal-title":"Diabetes, Obes Metab"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/S40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"M J Pereira","year":"2019","journal-title":"Drugs"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/B978-0-12-409547-2.12446-1","article-title":"Canagliflozin","volume":"8\u20138","author":"Z Khalid","year":"2024","journal-title":"Compr Med Chem III"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e20211287","DOI":"10.1590\/0001-3765202220211287","article-title":"Toxicological assessment of SGLT2 inhibitors metabolites using in silico\n                    approach","volume":"94","author":"DJ B Jesus","year":"2022","journal-title":"An Acad Bras Cienc"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/10590501.2013.763576","article-title":"Comparison of in silico models for prediction of mutagenicity","volume":"31","author":"N G Bakhtyari","year":"2013","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol\n                    Rev"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"624678","DOI":"10.3389\/FCHEM.2020.624678\/BIBTEX","article-title":"Identification of Chalcone Derivatives as Inhibitors of Leishmania infantum\n                    Arginase and Promising Antileishmanial Agents","volume":"8","author":"A R Garcia","year":"2021","journal-title":"Front Chem"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/CI500588J\/ASSET\/IMAGES\/MEDIUM\/CI-2014-00588J_0016.GIF","article-title":"DataWarrior: An open-source program for chemistry aware data visualization and\n                    analysis","volume":"55","author":"T Sander","year":"2015","journal-title":"J Chem Inf Model"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.YRTPH.2017.09.030","article-title":"Assessment of predictivity of volatile organic compounds carcinogenicity and\n                    mutagenicity by freeware in silico models","volume":"91","author":"L R Guerra","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMOA1811744\/SUPPL_FILE\/NEJMOA1811744_DATA-SHARING.PDF","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"2241665","DOI":"10.1080\/10717544.2023.2241665","article-title":"Development of canagliflozin nanocrystals sublingual tablets in the presence of\n                    sodium caprate permeability enhancer: formulation optimization,\n                    characterization, in-vitro, in silico, and in-vivo study","volume":"30","author":"S Fathy Elhabal","year":"2023","journal-title":"Drug Deliv"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.2217\/NNM-2018-0145","article-title":"Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic\n                    tumors in combination with radiotherapy","volume":"13","author":"A Angelopoulou","year":"2018","journal-title":"Nanomedicine"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"104630","DOI":"10.1016\/J.JDDST.2023.104630","article-title":"Formulation of canagliflozin hemihydrate-loaded bilosomes for the treatment of\n                    Type-2 diabetes mellitus: In vitro, in vivo and in silico molecular docking\n                    studies","volume":"86","author":"S Patil","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.31351\/VOL33ISS(4SI)PP43-56","article-title":"Formulation and Evaluation of Canagliflozin Self-nanomicellizing Solid\n                    Dispersion Based on Rebaudioside A for Dissolution and Solubility\n                    Improvement","volume":"33","author":"N A Jassem","year":"2024","journal-title":"Iraqi J Pharm Sci"},{"key":"ref75","first-page":"516","article-title":"Nanosuspension of Poorly Soluble Anti-Diabetic Drug for Enhancement of\n                    Solubility and Dissolution \u2013 Journal of University of Shanghai for Science and\n                    Technology","volume":"23","author":"P Padmanaban","year":"2021","journal-title":"J Univ Shanghai Sci Technol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3897\/FOLMED.64.E68866","article-title":"A recent solidification approach for nanosuspension: formulation, optimisation\n                    and evaluation of canagliflozin immediate release pellets","volume":"64","author":"N C Patel","year":"2022","journal-title":"Folia Med (Plovdiv)"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2577-1899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T23:02:44Z","timestamp":1751670164000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2577-1899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":75,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,7,4]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2577-1899","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}